Persons with type 1 diabetes require intensive insulin therapy to achieve lycaemic control, but side effects, including hypoglycaemia and weight gain, may reduce
treatment compliance. We hypothesise that add-on treatment of the short-acting glucagon-like peptide-1 receptor agonist, exenatide, to insulin therapy in persons with type 1 diabetes will reduce insulin requirements, glycaemic excursions and
body weight and improve glycaemic control without increasing the risk of hypoglycaemia.
The objective is to evaluate the safety and efficacy of the short-acting GLP-1RA, exenatide, administered three times per day (before each main meal) as add-on therapy to standard basal–bolus insulin regimen in persons with type 1 diabetes.